Safety of bilateral same-day intravitreal injections of anti-vascular endothelial growth factor agents

Figures & data

Table 1 Number of unilateral/bilateral injections per year and anti-VEGF used

Year	Ranibizumab	Aflibercept	Unilateral	Bilateral	Total
2011	738	0	586	152	738
2012	571	0	497	74	571
2013	1,652	197	1,367	482	1,849
2014	2,125	280	1,927	478	2,405
2015	1,777	346	1,753	370	2,123
2016	437	49	430	56	486
Total	7,300	872	6,560	1,612	8,172

Abbreviation: anti-VEGF, anti-vascular endothelial growth factor.

Table 2 Indications for injections

Year	Age-related macular degeneration	Diabetic retinopathy	Retinal vein occlusion	Myopic choroidal neovascularization	Other
2011	341	159	48	66	124
2012	321	103	70	37	40
2013	1,036	441	186	84	102
2014	1,339	559	303	128	76
2015	1,228	380	265	164	86
2016	292	83	50	41	20
Total	4,557	1,725	922	520	448

Table 3 Distribution of endophthalmitis per year and anti-angiogenic

Year	Acute intraocular inflammation		Culture-proven endophthalmitis		Total
	Ranibizumab	Aflibercept	Ranibizumab	Aflibercept
2011	1	–	–	–	1 (0.135%)
2012	–	–	–	–	0 (0%)
2013	1	2	–	–	3 (0.125%)
2014	9	2	–	–	11 (0.595%)
2015	2	2	1	–	5 (0.876%)
2016	–	–	–	–	0 (0%)
Total	13 (0.178%) 19 (0.233%)	6 (0.688%)	1 (0.014%) 1 (0.012%)	0 (0%)	20 (0.245%)